Related Experiment Video

Updated: Feb 16, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.8K

Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal?

Daniel F Hayes1

  • 1Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor.

JAMA Oncology
|December 16, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.2K

Related Experiment Videos

Last Updated: Feb 16, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.8K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

Articles linked to this work by shared authors, journal, and citation graph.

Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).

Journal of the National Cancer Institute·2026

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.

JAMA oncology·2025

Novel Postneoadjuvant Prognostic Breast Cancer Staging System.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.

Journal of the National Cancer Institute·2024

Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.

NEJM evidence·2024

Federal and Industry Sponsorship in US Cancer Clinical Trials.

JAMA oncology·2026

Trends in Meningioma Incidence, Treatment, and Imaging Surveillance.

JAMA oncology·2026

Racial and Ethnic Disparities in US Colorectal Cancer Mortality by County, Sex, and Age.

JAMA oncology·2026

Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.

JAMA oncology·2026

Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer.

JAMA oncology·2026

Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial.

JAMA oncology·2026

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Journal of the National Cancer Institute·2026

Periductal myxoid stroma identifies ductal carcinoma in situ at risk of invasive recurrence.

Journal of the National Cancer Institute·2026

Mayo Clinic classification of presacral tumors: evolution of classifications and systematic review of pathologies.

BJS open·2026

Survival outcomes of expansile versus infiltrative subtype in primary mucinous ovarian carcinomas: A retrospective study in Thailand.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026

Long-term prospective assessment of quality of life and physical function in malignant lymphoma patients undergoing chemotherapy.

Medicine·2026

Risk factors for local recurrence and metastasis of eyelid sebaceous carcinoma after complete excision: A large cohort study in Japan.

Indian journal of ophthalmology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us